Oppenheimer initiates NPS Pharmaceuticals (NPSP) at Outperform with a price target of $18....

|About: NPS Pharmaceuticals, Inc. (NPSP)|By:, SA News Editor

Oppenheimer initiates NPS Pharmaceuticals (NPSP) at Outperform with a price target of $18. "There are no direct competitors for Gattex and Natpara," writes analyst Boris Peaker, adding that investors shouldn't be wary of "owning a launch name" in this case because the company's "first-in-class compounds [should] generate substantial commercial traction given their therapeutic benefits." Shares +1.81% premarket.